v3.26.1
SEGMENT INFORMATION
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Segment Reporting [Abstract]    
SEGMENT INFORMATION
NOTE 11  - SEGMENT INFORMATION
 
The Company operates as a single operating segment in the research and development of innovative treatments for pancreatic cancer based on siRNA. The Company’s CODM is its Chief Executive Officer (CEO). The CODM reviews the Company’s performance on a consolidated basis. As such, the segment’s loss is the Company’s consolidated net loss and the segment’s assets are the Company’s consolidated assets.
 
The CODM uses the information primarily to evaluate the Company’s performance and allocate resources. This includes reviewing key financial metrics such as budget versus actual expenditures, tracking progress on research and development milestones, and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows the CODM to monitor the Company's performance and make strategic adjustments as needed to support its operational and financial goals.
 
The CODM reviews the Company’s results on a consolidated basis. As such, information on segment loss and significant expenses is similar to the Company’s consolidated statements of operations. The CODM is also regularly provided with information on significant ordinary-course expenses, including the following expenses. The Company’s management does not segregate the Company’s business for internal reporting.
 
   
Three months ended
March 31
  
   
2026
    
2025
  
Clinical trials and other payments to R&D-related service providers
  
$
891
    
$
156
  
R&D payroll and related expenses, other than share-based compensation
    
263
      
369
  
R&D share-based compensation expense
    
130
      
-
  
G&A payroll and related expenses, other than share-based compensation
    
241
      
332
  
G&A share-based compensation expenses
    
215
      
21
  
Professional services
    
783
      
525
  
Depreciation expenses
    
2
      
4
  
Other segment expenses (*)
    
224
      
243
  
Operating loss
    
2,749
      
1,650
  
Interest income
    
(32
)
    
(2
)
Interest expense
    
-
      
11
  
Other financing expense (income), net
    
16
      
76
  
Income taxes
      
**
      
**
Net loss
  
$
2,733
    
$
1,735
  
                 
Segment assets
  
$
4,602
    
$
8,308
  
Expenditures for segment assets
    
-
      
(6
)
Segment liabilities
  
$
4,311
    
$
5,722
  
 
  (*)
Other segment expenses include mainly general and administrative-related expenses, such as rent and maintenance expenses, travel and HR expenses.
  (**)
Represents an amount less than $1
NOTE 15  - SEGMENT INFORMATION
 
   
The Company operates as a single operating segment in the research and development of innovative treatments for pancreatic cancer based on siRNA. The Company’s CODM is its Chief Executive Officer (CEO). The CODM reviews the Company’s performance on a consolidated basis. As such, the segment’s loss is the Company’s consolidated net loss and the segment’s assets are the Company’s consolidated assets.
 
The CODM uses the information primarily to evaluate the Company’s performance and allocate resources. This includes reviewing key financial metrics such as budget versus actual expenditures, tracking progress on research and development milestones, and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows the CODM to monitor the Company's performance and make strategic adjustments as needed to support its operational and financial goals.
 
  a.
Segment disclosures
 
The CODM reviews the Company’s results on a consolidated basis. As such, information on segment loss and significant expenses is similar to the Company’s consolidated statements of operations. The CODM is also regularly provided with information on significant ordinary-course expenses, including the expenses listed in the below table. The Company’s management does not segregate its business for internal reporting.
 
   
Year ended December 31
  
   
2025
    
2024
  
Clinical trials and other services from R&D-related service providers
  
$
5,030
    
$
1,893
  
R&D payroll and related expenses, other than share-based compensation
    
1,801
      
1,231
  
R&D share-based compensation expenses
    
-
      
2,424
  
G&A payroll and related expenses, other than share-based compensation
    
1,527
      
1,154
  
G&A share-based compensation expenses
    
134
      
3,438
  
Professional services
    
2,103
      
1,632
  
Depreciation expenses
    
14
      
25
  
Other segment expenses (*)
    
1,023
      
774
  
Operating loss
    
11,632
      
12,571
  
Interest income
    
(155
)
    
(28
)
Interest expense
    
13
      
27
  
Other financing expense, net
    
419
      
3,939
  
Income taxes
    
3
      
10
  
Net loss
  
$
11,912
    
$
16,519
  
                 
Segment assets
  
$
7,215
    
$
2,863
  
Expenditures for segment assets
  
$
(9
)
  
$
(22
)
Segment liabilities
  
$
4,612
    
$
6,852
  
 
   
(*) Other segment expenses include mainly general and administrative-related expenses, such as rent and maintenance expenses, travel and HR expenses.
 
  b.
Entity-Wide disclosures
 
All of the Company’s long-lived assets are located in Israel.